Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01866774
Other study ID # Q4415
Secondary ID
Status Terminated
Phase N/A
First received January 3, 2013
Last updated October 22, 2015
Start date May 2013
Est. completion date April 2015

Study information

Verified date October 2015
Source Queen's University
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

Triaging new pediatric gastroenterology consultations is challenging as both inflammatory and non-inflammatory gastrointestinal (GI) diseases can present with non-specific chronic abdominal pain and/or diarrhea. Examples of inflammatory GI diseases include Crohn's disease, ulcerative colitis and celiac disease and non-inflammatory GI diseases lactose intolerance, irritable bowel syndrome and non-ulcer dyspepsia. Inflammatory GI diseases require different investigations and treatment than non-inflammatory GI diseases and ideally, would be identified early. Higher priority triage of these patients would allow timely organization of further investigations including pertinent laboratory testing, radiologic studies and gastrointestinal endoscopies. These more invasive procedures are not needed in most patients presenting with non-specific gastrointestinal symptoms. Therefore, the investigators do not routinely ask for screening laboratory testing or other studies in children referred to our clinic.

Non-invasive screening tests for GI disorders may aid in appropriately triaging new consultations to pediatric gastroenterology. Calprotectin is a protein found in inflammatory cells called neutrophils. The concentration of calprotectin in stool reflects the presence of an inflammatory process occurring in the GI tract. Thus, testing for calprotectin has been proposed as a potentially useful test for detecting some inflammatory GI diseases, most notably Crohn's disease and ulcerative colitis. Alternatively, a simple gastrointestinal questionnaire of "red flag" symptoms and family history of GI disorders may also be of benefit. The investigators hypothesize that the use of fecal calprotectin and a screening GI questionnaire will aid in identifying children at higher risk of an inflammatory GI disorder. Subsequently, higher priority triaging of these patients will decrease the time to diagnosis of inflammatory GI disease.

This will be a single centre, stratified, randomized clinical trial conducted in Kingston, Ontario, Canada. Patients referred to the pediatric gastroenterology service without a known diagnosis for non-specific chronic abdominal pain and/or diarrhea will be asked to participate in the study. All patients who meet the inclusion criteria will be consented by telephone with a standard form. Consenting patients will be mailed the GI questionnaire and the fecal calprotectin test kit. The fecal calprotectin test kid includes instructions, a stool collection kit and return postage. All patients will be given the next available appointment with a pediatric gastroenterologist. Patients will then be randomized to receive either usual care (50%, 40 patients) or to have a screening fecal calprotectin (FC) measurement (50%, 40 patients). Patients in the FC group will have FC measured by the Quantum Blue® Rapid Calprotectin Assay. If the calprotectin level is high (above 50 μg/g), the patient will be contacted again by telephone and given a new appointment time (within 14 working days). This study may have a positive impact by demonstrating a novel method for decreasing the time to diagnosis of inflammatory GI disease.


Recruitment information / eligibility

Status Terminated
Enrollment 15
Est. completion date April 2015
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender Both
Age group 5 Years to 17 Years
Eligibility Inclusion criteria:

- have been referred to the pediatric gastroenterology service at the Kingston University Hospital Network for abdominal pain or chronic diarrhea

- be between 5 to 17 years of age

Exclusion criteria:

- overt signs and symptoms of an inflammatory gastrointestinal disease in the referral letter (will triaged with high priority within 14 working days

- evidence of GI bleeding, extraintestinal manifestations of inflammatory bowel disease, significant weight loss or laboratory abnormalities

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic


Intervention

Other:
Fecal calprotectin level


Locations

Country Name City State
Canada Kingston University Hospital Network Kingston Ontario
Canada Queen's University Kingston Ontario

Sponsors (1)

Lead Sponsor Collaborator
Queen's University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to final diagnosis Up to 12 months from enrollment No
See also
  Status Clinical Trial Phase
Completed NCT03269305 - An Audit on Management of Chronic Diarrhea
Completed NCT03876717 - Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea Phase 4
Not yet recruiting NCT03598010 - Safety, Tolerability and Preliminary Efficacy of Lenodiar Pediatric in Diarrhea N/A
Completed NCT05690321 - Opium Tincture Against Chronic Diarrhea - Patients Phase 2
Completed NCT01545063 - CAre of Patients With PArenteral Nutrition At Home N/A
Completed NCT05702190 - Opium Tincture Against Chronic Diarrhea - Healthy N/A
Not yet recruiting NCT05811091 - Pathological Patterns in Chronic Diarrhea With Normal Colonoscopy
Not yet recruiting NCT05724381 - Auramine Phenol Staining Technique for Revealing Different Coccidian Parasites
Recruiting NCT01070277 - Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea N/A
Completed NCT02642250 - Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea Phase 2/Phase 3
Recruiting NCT06152289 - Development of New Diagnostic Tools in Capsule Endoscopy
Completed NCT03270085 - Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption Phase 2
Completed NCT05130047 - Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM) Phase 2
Recruiting NCT03261297 - Epidemiology of Chronic Diarrhea Among Children Admitted to Gastroenterology Unit at Assuit University Children Hospital N/A
Completed NCT01840891 - Secondary Lactose Intolerance Due to Chronic Norovirus Infection N/A
Completed NCT03143517 - Fecal Calprotectin Collection Protocol